CEL-SCI bias analysis confirms Multikine survival benefit; 5-year survival 73% vs 45% in target population

CEL SCI CORP

Bias analysis found no confounding baseline parameters; treatment and control arms are balanced, no bias detected.
Target population (no lymph node, low PD-L1): Multikine 5-year survival 73% vs 45% control; hazard ratio 0.35.
Company plans 212-patient confirmatory registration study with FDA agreement.
Entire Phase 3 study of 923 patients also showed no bias; CEO notes high confidence in repeating survival benefit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.